Results showed that GLPP increased the synthesis of bile acids through enhancing cholesterol 7-alpha-monooxygenase (CYP7A1) and 25-hydroxycholesterol 7-alpha-hydroxylase (CYP8B1) expression, while the increased bile acids promoted the farnesoid X receptor- small heterodimer partner (FXR-SHP)/fibroblast growth factor (FGF) pathway, which finally inhibited fatty acid synthesis and thus improved the steatosis in NAFLD. The gene discussed is CYP7A1; the disease is metabolic dysfunction-associated steatotic liver disease.